Skip to main content


Fig. 2 | Clinical and Translational Medicine

Fig. 2

From: EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients

Fig. 2

Maximum somatic allele frequency (MSAF) and osimertinib treatment outcomes. a The MSAF level between responders and non-responders (median: 9.9% vs 10.7%, P = 0.705, Mann–Whitney test). b Overall response rate between patients with MSAF-low and MSAF-high (48.0% vs 50.0%, P = 0.886, χ2 test), according to the median value of MSAF. c Progression-free survival stratified by MSAF-low and MSAF-high patients (P = 0.370, log-rank test)

Back to article page